First elected: 4th July 2024
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Sojan Joseph, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Sojan Joseph has not been granted any Urgent Questions
Sojan Joseph has not been granted any Adjournment Debates
Sojan Joseph has not introduced any legislation before Parliament
Sojan Joseph has not co-sponsored any Bills in the current parliamentary sitting
I can confirm that a cut of the field to remove the thistles and ragwort was completed by Sunday 8th September. The cut was started following an ecological walkover visit on Monday 2nd September to ensure that the works could go ahead without impacting nesting birds.
There are no plans to abolish parking charges for National Health Service staff.
All trusts that charge for hospital car parking provide free parking to ‘in-need groups’, which include NHS staff working overnight, frequent outpatient attenders, disabled people and parents of children staying overnight in hospital.
The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of our intensive work, some issues have been resolved. Many strengths of lisdexamfetamine and all strengths of atomoxetine capsules and guanfacine prolonged-release tablets are now available. We are working to resolve medicine supply issues, where they remain, for some strengths of lisdexamfetamine and methylphenidate. These are anticipated to resolve by August and October 2024, respectively.
We have engaged with all suppliers of methylphenidate prolonged-release tablets to discuss the challenges faced and their actions to address them. We are asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.
The Department has worked with specialist clinicians to develop management advice for National Health Service clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets. We would expect ADHD service providers and specialists to follow our guidance to offer rapid response to primary care teams seeking urgent advice or opinion for the management of patients including those known to be at a higher risk of adverse impact because of these shortages.
To aid ADHD service providers and prescribers further, we have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients, which is available at the following link:
https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/